CDX
JIMT-1
Tumor indication
Breast
Tumor subtype
Ductal Carcinoma
Description
JIMT-1 (Breast Cancer CDX Model)
The JIMT-1 breast cancer cell line was derived from a patient with ductal carcinoma. It is HER2-positive but resistant to trastuzumab, making it unique among breast cancer models. JIMT-1 is widely applied in resistance mechanism studies. Its biology reflects clinically relevant HER2-driven but refractory breast cancers.
Key Features:
- Derived from ductal breast carcinoma.
- HER2-positive, trastuzumab-resistant.
- Aggressive xenograft growth.
- Represents therapy-resistant breast cancer.
Applications:
JIMT-1 is used to study resistance in HER2-positive breast cancer. Researchers test novel HER2-targeted and combination therapies with this model. It supports biomarker identification for therapy resistance. Its defined biology makes it critical in preclinical breast cancer pipelines.
Details
- Tumor indication
- Breast
- Tumor subtype
- Ductal Carcinoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.